Ergoteles’s Vigil Neuroscience VIGL Stock Holding History

Ergoteles’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-28,533	Closed	-$260K	–	1916
2022 Q3	$260K	Buy	+28,533	New	+$209K	0.01%	1055

Other funds holding VIGL

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Ergoteles's VIGL Position: Q4 2022 in Review

Ergoteles sold out of Vigil Neuroscience (VIGL) in Q4 2022, closing a stake of 28,533 shares — an estimated $260K sold.

Ergoteles first reported a position in VIGL in Q3 2022 and held it in 1 quarter. The position peaked at $260K in Q3 2022. 37 funds tracked by Wall St. Rank hold VIGL as of Q4 2022.

Ergoteles reported no remaining Vigil Neuroscience position as of Q4 2022 after selling out during the quarter.
Ergoteles sold 28,533 Vigil Neuroscience shares in Q4 2022, an estimated $260K.
Ergoteles first reported a position in Vigil Neuroscience in Q3 2022 and held it in 1 quarter.
Ergoteles's Vigil Neuroscience position peaked at $260K in Q3 2022.
37 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.